IMI2 – Call 5

IMI2 – Call 5 was launched on 9 July 2015 with the following topics:

  • Patient perspective elicitation on benefits and risks of medicinal products, from development through the entire life cycle, to inform the decision-making process by regulators and health technology assessment bodies
  • Diabetic kidney disease biomarkers (DKD-BM)
  • Inflammation and ad: modulating microglia function – focussing on TREM2 and CD33
  • Understanding the role of amyloid imaging biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment (from pre-dementia to dementia)
  • Evolving models of patient engagement and access for earlier identification of Alzheimer’s disease: phased expansion study
  • From ApoE biology to validated Alzheimer’s disease targets

More information on the topics can be found in IMI’s press release and in the Call text. Other relevant documents, including documents for applicants, the list of expert reviewers, and the independent observers’ reports of the evaluations, can be found on the IMI2 Call documents page.



The projects resulting from IMI2 – Call 5 are:

  • ADAPTED - Alzheimer's disease apolipoprotein pathology for treatment elucidation and development
    factsheet | website
  • AMYPAD - Amyloid imaging to prevent Alzheimer’s disease
    factsheet | website
  • BEAT-DKD - Biomarker enterprise to attack DKD
    factsheet | BEAT-DKD
  • MOPEAD - Models of patient engagement for Alzheimer’s disease
    factsheet | website
  • PHAGO - Inflammation and AD: modulating microglia function - focussing on TREM2 and CD33
    factsheet | website
  • PREFER - Patient preferences in benefit risk assessments during the drug life cycle
    factsheet | website


Call statistics

  • Proposals submitted: 25
  • Inadmissible & ineligible proposals: 3
  • Proposals recommended for funding: 6
  • Proposals not recommended for funding: 16